Molecular Tumor Profiling in Oncology Patients with Multiple Genomic Variants

Session Description

This session will include three separate case reports of patients who received genomic testing on multiple platforms. It will describe the utility of these tests beyond standard of care options, and we will discuss integration and interpretation of genomic test results to inform selection of targeted therapies. Furthermore, timing of biopsy according to stage and disease progression will be discussed. This presentation originally planned for July 25 had to be rescheduled due to technical difficulties. Dr. Powell will share a 45-minute recorded presentation followed by her
responding to questions.

Learning Objectives

At the conclusion of this session, participants should be able to:

1. Explain clinical and molecular aspects of somatic genomic variants in advanced tumors.
2. Discuss how next generation sequencing can inform treatment decisions for oncology patients.
3. Describe how liquid biopsy and solid tumor sequencing can inform targeted therapy selection in patients according to cancer stage.

Target Audience

All medical and healthcare professionals and researchers interested in understanding cancer genomic testing and somatic and germline variant interpretation methods. This series is presented as a collaboration between ClinGen Somatic, VICC, and ACMG consortia.

Agenda

Presentation followed by live Q&A. 

Moderator

Beth Pitel, M.S., CG(ASCP) CM

Clinical Variant Scientist, Division of Laboratory Genetics and Genomics

Assistant Professor, Department of Laboratory Medicine and Pathology, Mayo Medical School

Presenter

Emily Powell, PhD, ACRP-CP

Principal Genomic Scientist and Manager of Precision Genomics, Parkview Health

Adjunct Clinical Assistant Professor of Medicine, Indiana University School of Medicine- Fort Wayne

Planning Committee:

Beth Pitel, MS, CG(ASCP)

Gordana Raca, MD, PhD, FACMG

Manuela Benary, PhD

Jason Saliba, PhD

Jane Radford, MHA, CHCP

Claudia Barnett 

Continuing Medical Education (CME AMA & CME Other)

Accreditation

The American College of Medical Genetics and Genomics is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation

The American College of Medical Genetics and Genomics designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

The American Medical Association (AMA) defines physicians as those individuals who have obtained an MD, DO, or equivalent medical degree from another country. Non-physicians may request a certificate of attendance for their participation.

Claiming your Educational Credits

Complete the activity and carefully complete the evaluation form. The deadline to claim educational credits is within 30 days of the date of the activity. Educational credit requests after this date will not be accepted.

Accredited Continuing Education Financial Disclosure

The American College of Medical Genetics and Genomics (ACMG) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide Accredited Continuing Education (ACE) for physicians. ACMG is an organization committed to improvement of patient care and general health by the incorporation of genetics and genomics into clinical practice.

ACMG has implemented the following procedures to ensure the independence of ACE activities from commercial influence/promotional bias, the Accreditation Council for Continuing Medical Education (ACCME) requires that providers (ACMG) must be able to demonstrate that: 1) everyone in a position to control the content of an ACE activity has disclosed all financial relationships that they have had in the past 24 months with ineligible* companies; 2) ACMG has implemented a mechanism to mitigate relevant financial relationships; and 3) all relevant financial relationships with ineligible companies are disclosed to the learners before the beginning of the educational activity. The learners must also be informed if no relevant financial relationships exist.
*Ineligible companies are defined as those whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

ACMG Education Policies

Please review the policies below regarding the ACMG Education program

• Financial Disclosures and Mitigation Procedure
• ACMG Content Validation Policy
• ACMG Content Branding Policy

All of the relevant financial relationships listed for these individuals have been mitigated.